We are a consumer driven, pharma company, devoted to research and development of beneficial products based on our Mucoadhasive Buccal Extended Release Drug Delivery Technology
Lasting Effect Consumer Pharma has developed a proprietary mucoadhesive buccal extended-release technology capable of delivering a broad spectrum of active pharmaceutical ingredients (APIs) through the buccal mucosa, as well as for topical exposure, for up to 8 hours. Our technology addresses critical limitations inherent in existing buccal delivery systems and represents a differentiated drug delivery route with significant advantages over conventional oral administration.
Our technology offers an innovative pharmaceutical delivery system that bypasses hepatic first-pass metabolism, reduces dosing frequency, enhances bioavailability, and provides a patient-friendly alternative for populations with dysphagia or gastrointestinal dysfunction. The technology is protected by comprehensive intellectual property and utilizes Generally Recognized as Safe (GRAS) components in its basic formulation.
We build upon more than 5 years of R&D by a team of founders with more than 180 combined years of experience in pharmaceutics, organic chemistry and dentistry.
MBA, 25 years of experience as entrepreneur in food development.
2 successful new food product launches.
Specializes in user compliance and consumer decision making.
Highly experienced in operating and managing under high uncertainty.
Experienced in developing new consumer goods concepts and introducing new products to the market.
Partner, Investor relations
Ex Colgate’s Consultant and its Business Representative in Israel for identifying technologies for acquisition, investment and cooperation.
Partner, Chemistry and Cannabis
Organic Chemist expert in innovation in the life science sector. As Director of Life Science of T3 (Tech. transfer office of the Technicon) he set up Companies like Nano-Ghost and Cannasoul.
He is the founder of Mental Heal, a company that develops a drug for the negative symptoms of schizophrenia and Glaucopharm, a company dealing with the treatment for Glaucoma.
Partner, Oral germs and Clinical Trails
BSc. MED in 2005, DMD in 2007, MPH in 2012, Ph.D. In 2020 from the Hebrew University – Faculty of Dentistry in Hadassah. Doctor of Dentistry, research and technology consultant for dental and pharma startups.
Member of the Faculty of Dentistry and Head of Dental Research, Hadassah University. Currently serves as the President of the Israel Society for Public Health in Israel.
Partner, Regulation and Toxicology
Expert in the regulation of toxicology. Pre-clinical development and safety assessment of innovative drugs, chemicals and food ingredients.
Over 20 years in the field of regulatory toxicology. Worked in Teva, Agis, Perrigo, Padgis and several Startup companies. Serves as Head of Preclinical Development and Toxicology at Perrigo/Padagis since 2003 to date.
